t
SkinBioTherapeutics plc announced on 25 June 2026 that its Chief Financial Officer, Emily Bertram, will leave the company on 30 June 2026. The Company has engaged an Interim CFO on a non-Board basis, and a process to hire a new permanent CFO is underway.
| Date | 25 Jun 2026 |
| Time | 12:00:00 |
| Category | Board changes |
| ID | 8023J |
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company" or the "Group")
Directorate Change
25 June 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that Emily Bertram, Chief Financial Officer, has decided to leave the business on 30 June 2026.
During her tenure, Emily has demonstrated the highest standards of professionalism, integrity and leadership, and has made a significant contribution to the Company's financial stewardship and governance. She was instrumental in identifying and escalating the issues to the Board regarding the former CEO's conduct and she has worked closely with Alyson Levett and Rachel Parsonage to ensure the business continues to operate as usual. She is ensuring an orderly handover before her departure.
The Company has engaged an Interim CFO, on a non-Board basis, who brings extensive experience as a Chartered Accountant and AIM-listed plc CFO, including a demonstrable track record in strengthening financial controls, corporate governance and reporting standards. The process for hiring a new permanent CFO is underway.
The Board wishes to express its gratitude for Emily's dedication and commitment, and extends its best wishes for her future career.
-Ends-
For more information please contact:
|
SkinBioTherapeutics plc |
|
|
Singer Capital Markets (Nominated Adviser & Broker) |
+44 (0) 020 7496 3000
|
|
Vigo Consulting |
+44 (0) 20 7390 0230 |
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life sciences company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.
The Company's strategic approach to skin health is via two routes - tackling skin issues from the 'outside in' and the 'inside out'. The 'outside in' approach is represented by topical creams, and from the 'inside out', via oral supplement solutions which impact the skin via different axes such as the gut and the brain.
SkinBio's products and services are developed through evidence-based science and commercially focused innovation with the aim of supporting skin health, well-being, repair and beauty. SkinBio also has a contract manufacturing and distribution arm related to skin health and other healthcare products.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.SkinBioTherapeutics.com.